Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 7829558 Fused ring heterocycle kinase modulators

Patent 7829558 was granted and assigned to SGX Pharmaceuticals on November, 2010 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Current Assignee

SGX Pharmaceuticals

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

November 9, 2010

Patent Application Number

12235426

Date Filed

September 22, 2008

Patent Citations Received

US Patent 11667632 2-(1H-indazol-3-yl)-3H-imidazo[4,5-C]pyridines and their anti-inflammatory uses thereof

0

US Patent 11697649 Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof

0

US Patent 11684615 Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors

0

US Patent 12012401 Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide

0

US Patent 11780823 Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors

Patent Primary Examiner

D. Margaret Seaman

Patent abstract

The present invention provides novel fused ring heterocycle kinase modulators and methods of using the novel fused ring heterocycle kinase modulators to treat diseases mediated by kinase activity.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 7829558 Fused ring heterocycle kinase modulators

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool